MARC BEER

The Boston-based Medtech Company is forming various products that treat pelvic infections like the urinary infection and disease which affects mostly over two hundred and fifty million women all over the world.

 

Renovia Company launched the first product which was known as Leva, and the FDA gladly received the product and approved that the product was safe to be used in April.

 

Longwood Fund which is a healthcare investment company invested heavily in Renovia Company and later joined the Series B round that was led by New York-based councilors and advisors.

 

The fund that was provided was to help in further developing, and testing of more products that would be used for diagnosis and a new group of the Leva device was to be launched.

 

Through the Longwood Fund, Marc Beer and other employees in the Renovia company have been able to provide a better diagnose and treat women affected by pelvic floor disorders thereby improving their lives more excellently and make them believe that they will live for long.

 

When they receive the funds from Longwood Fund, they will be able to bring together their innovative ideas and advance their technological types of equipment thus facilitating their customers with better information and thereby informing them of the new treatment options, and therefore the clients will have a better knowledge and understanding of pelvic floor disorders.

 

As Marc Beer was working at his previous company, he was able to develop a medicine for a rare form of high cholesterol, but the FDA accused him that the drug he launched which was known as Juxtapid was an effective treatment for heart conditions and not pelvic floor disorders in women.

 

The company is now charged with a case and have to pay forty million dollars for there was improper marketing of Juxtapid.

 

Marc Beer also works as a strategic consultant in Waltham biotechnology as the CEO of ViaCell which the biotechnology company specializes in gathering, conservation, and development of the umbilical cord blood stem cells.

 

The company grew very fast and ended up having over three hundred employees, and in two thousand and seven, it was acquired by PerkinElmer. He also worked as a member of a board of directors of Erytech Pharma and a former member of the Mass life Science Board of the Commonwealth.

 

Marc was also a Founding Chairman of the Good Start Genetics Company, a member of the Miami University Advisory Council and before he was a member of the Notre Dame Research and Commercialization as the advisor of the committee.

 

In conclusion, we find that Marc has held a lot of positions in many of the companies and has been a person of great importance especially to the women suffering from pelvic floor disorders. Learn more : https://www.slideshare.net/MarcBeer